CN103848894A - Novel compound containing daptomycin structure as well as preparation method and application thereof - Google Patents
Novel compound containing daptomycin structure as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN103848894A CN103848894A CN201210527557.1A CN201210527557A CN103848894A CN 103848894 A CN103848894 A CN 103848894A CN 201210527557 A CN201210527557 A CN 201210527557A CN 103848894 A CN103848894 A CN 103848894A
- Authority
- CN
- China
- Prior art keywords
- daptomycin
- preparation
- purposes
- medicine
- compd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical group C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 26
- 108010013198 Daptomycin Proteins 0.000 claims description 44
- 229960005484 daptomycin Drugs 0.000 claims description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 206010014801 endophthalmitis Diseases 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 229920001427 mPEG Polymers 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 208000030533 eye disease Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- -1 polyoxyethylene Polymers 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000011806 microball Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 208000001860 Eye Infections Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 210000001742 aqueous humor Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 210000002159 anterior chamber Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- LVQNNZNQNYTFDS-UHFFFAOYSA-N 2-acetyldecanedioic acid Chemical compound C(C)(=O)C(C(=O)O)CCCCCCCC(=O)O LVQNNZNQNYTFDS-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 0 CC*=C(CC1)[*@](C(C(C)OC2=*=C([C@]([C@@](C)CC(O)=O)NC(C(CO)NC(C*(C([C@](C3)NC([C@@](C)NC(C(CC(O)=O)NC([C@@](CCCNC(CCCCCCCCC(C(C)(C)OC(*(C)C)=O)=O)=O)NC(C*4)=O)=O)=O)=O)=O)=C3O)=O)=O)N[C@]2CC2=*c3c2cccc3)C4=O)C1=C Chemical compound CC*=C(CC1)[*@](C(C(C)OC2=*=C([C@]([C@@](C)CC(O)=O)NC(C(CO)NC(C*(C([C@](C3)NC([C@@](C)NC(C(CC(O)=O)NC([C@@](CCCNC(CCCCCCCCC(C(C)(C)OC(*(C)C)=O)=O)=O)NC(C*4)=O)=O)=O)=O)=O)=C3O)=O)=O)N[C@]2CC2=*c3c2cccc3)C4=O)C1=C 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 206010015943 Eye inflammation Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000034700 Vitreous opacities Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000009775 high-speed stirring Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010011033 Corneal oedema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 201000004778 corneal edema Diseases 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940021392 cubicin Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000001232 limbus corneae Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 208000026475 palpebral edema Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a novel compound containing a daptomycin structure as well as a preparation method and an application of the compound. Drugs prepared by the novel compound containing the daptomycin structure have better effects than medicines or drugs in other forms in treatment of endoophthalmitis diseases.
Description
Technical field
The invention discloses the new compound that contains daptomycin structure and preparation method and the purposes of this compound.
Background technology
Daptomycin (Daptomycin) is by Lilly (gift comes) company's original research, a cyclic lipopeptide microbiotic of Cubist drugmaker exploitation.Daptomycin (Daptomycin) (trade(brand)name cubicin) is used for the treatment of the concurrency skin and the skin texture that are caused by some Gram-positive sensitive strains to be infected, as abscess, operative incision infect and skin ulcer.The mechanism of action of daptomycin is different from other microbiotic, it is by upsetting cytolemma to amino acid whose transhipment, thereby hinder the biosynthesizing of bacteria cell wall peptidoglycan, change the character of cytoplasmic membrane, thereby it can also leak its content to reach the object of sterilization by destroying the cytolemma of bacterium in addition, therefore bacterium daptomycin is produced to resistance may be more difficult.In the time treating comparatively serious eye inflammation, daptomycin can produce positive result for the treatment of.
Endophthalmitis is a kind of inflammation of involving eyeball internal layer, vitreum, sclera, and most endophthalmitis are due to bacterium or fungi infestation.Bacterium route of infection can be wound, and the eyeball wound that operation causes can be also haematogenous (bacterium menses spread and cast to intraocular).The symptom of endophthalmitis is usually heavier, mainly contains ophthalmodynia, hyperemia, serious photophobia and eyesight and sharply declines.The symptom of endophthalmitis is usually heavier, mainly contains ophthalmodynia, hyperemia, serious photophobia and eyesight and sharply declines.
The new compound that contains daptomycin of preparing at this patent directly wraps up the nanometer formulation that daptomycin makes and compares with polymkeric substance is simple when endophthalmitis in treatment, the medicine that this patent is invented medication effect in the time of the eye disease model for the treatment of endophthalmitis and severe infections is very good, and effect far surmounts the nanometer formulation of the simple directly parcel of polymkeric substance daptomycin.
Summary of the invention
Of the present invention theing contents are as follows:
The segmented copolymer that the invention discloses the daptomycin coupling shown in following formula I, its structure is as follows:
Wherein PEG refers to polyoxyethylene glycol, and molecular weight is 100-100000, and wherein n does not represent stationary digital, is the integer of 1-200, preferably 1-100.
The preparation method of multipolymer of the present invention, is characterized in that:
1) obtain compd A with methoxy poly (ethylene glycol) amine and citric acid reactions;
2) reaction of the sebacic acid of compd A and ethanoyl obtains polymer B, and wherein n does not represent stationary digital, is the integer of 1-200, preferably 1-100;
3) polymer B is reacted and is obtained final product with daptomycin C;
Daptomycin C
Wherein daptomycin is purchased.The required solvent of described chemical step of the final product of the synthetic new compound that contains daptomycin is selected from: one or more in benzene, toluene, pyridine, tetrahydrofuran (THF), chloroform, tetracol phenixin, methylene dichloride, methyl alcohol, ethanol, methylene dichloride, dimethyl sulfoxide (DMSO), DMF.
The compound of new system can be prepared into the nanometer formulation that is suitable for topical, microball preparation.Purposes is the medicine of preparation treatment endophthalmitis.
Preparation method of the present invention is specific as follows:
1) sebacic acid is refluxed in diacetyl oxide, form ethanoyl-sebacic acid;
2) methoxy poly (ethylene glycol) amine and citric acid are dissolved in solvent, and hybrid reaction is spent the night, the dry compd A that obtains;
3) ethanoyl-sebacic acid is mixed to reaction at 100-200 DEG C, reaction times 10min to 10h with compd A; After question response mixture is cooling, washing, the dry polymer B that obtains;
4) by daptomycin C and polymer B as for 1-96 hour in solvent, after ultrasonic reaction 1-60 minute, in baking oven, foster and obtain formula I polymkeric substance, then homogenizer high-speed stirring 1-20 minute in subzero 30 DEG C of 0-, rotation volatilization obtains crude product, and aftertreatment obtains the nanometer formulation of end product formula I polymkeric substance.
Its reaction equation is as follows:
The polymkeric substance that what the present invention obtained contain daptomycin structure, is easy to dissolve in water, and its transformation period extend much than daptomycin, such new compound effect in the time of the model for the treatment of endophthalmitis is splendid.
The nanometer formulation that the end product of preparing at this patent is made treatment eye disease relatively in, the medication effect of this patent new compound is very good, surmounts the nanometer formulation that is directly wrapped up daptomycin (not with daptomycin coupling) by polymkeric substance completely.
Brief description of the drawings:
The nuclear magnetic resonance map of the end product of Fig. 1 embodiment 1.
Nanoparticle, the sebacic acid-glycol copolymer that Fig. 2 embodiment 1 makes directly wraps up medicine accumulative releasing degree and the time chart of daptomycin nanoparticle and daptomycin ordinary preparation.
Embodiment
Specific embodiment is described in further detail the present invention below, but the present invention not only limits to following examples.
Preparation Example is as follows:
Embodiment 1
1) mixture of sebacic acid 80g in 800ml diacetyl oxide refluxes, to form ethanoyl-sebacic acid;
2) methoxy poly (ethylene glycol) amine 6.5g, citric acid 73mg, dicyclohexylcarbodiimide 172mg and pyridine 8.7mg mix and add 32ml methylene dichloride, at room temperature stir and spend the night; Then wash with ether, and dry under vacuum, obtain polymkeric substance;
3) by the 1st) step and the 2nd) step Product mix puts into flask, and at 180 DEG C, decompression contains intermingle with reaction 1 hour; Treat that polymkeric substance is cooled to room temperature chloroform and dissolves, and also dry by petroleum ether;
4) the 800mg polymkeric substance of 120mg daptomycin and step 3 is put into the dichloromethane solution 48 hours of 8ml dimethyl sulfoxide (DMSO) and 12ml; Ultrasonic 3 minutes; Then insert in baking oven 1 hour; In subzero 10-20 degree, homogenizer ultra-high speed stirs 3 minutes, then puts into 1% polyvinyl alcohol solution 600 and turns and stir 2 hours; Freeze-drying after centrifugal collection, obtains the nanoparticle of end product.
Embodiment 2
1) methoxy poly (ethylene glycol) amine 3.5g, citric acid 45mg, dicyclohexylcarbodiimide 200mg and pyridine 6mg mix and add 20ml methylene dichloride, at room temperature stir and spend the night; Then wash with ether, and dry under vacuum;
2) ethanoyl-sebacic acid 20g (being purchased) and the 1st step Product mix are put into flask, at 175 DEG C, react 1.5 hours; Treat that polymkeric substance is cooled to room temperature chloroform and dissolves, and with petroleum ether the dry polymkeric substance (structure or with homemade slightly different, molecular weight or different because being purchased quality) that obtains;
3) 35mg daptomycin and this polymkeric substance 150mg are put into the solution being mixed by 1ml methyl alcohol and 1ml methylene dichloride; Ultrasonic 2 minutes; Then insert in baking oven 12 hours; In subzero 10-20 degree, homogenizer high-speed stirring 2 minutes, product is put into 8% cholic acid solution 600 and is turned and stir 4 hours; Freeze-drying after centrifugal collection, obtains the microballoon of new compound.
Effect experiment is as follows:
Sample prepared by embodiment 1-2 and and sebacic acid-glycol copolymer directly the nanoparticle medicine group of the daptomycin of parcel (there is not chemical coupling reaction, daptomycin does not have structural changes), daptomycin ordinary preparation (powder injection) carries out respectively the drug action test of stability test, drug release in vitro test and endophthalmitis.
Stability test:
By the nanoparticle medicine group of the daptomycin of 1 group of sample of preparing of embodiment and sebacic acid-glycol copolymer parcel, daptomycin ordinary preparation is got with amount (in daptomycin) and is measured respectively absorbance.Then put into 20 degree incubator 3 months for three groups, take out subsequently and measure nanometer absorbance, the absorbance front and back of the daptomycin of the visible embodiment 1-2 group of result and ordinary preparation group are without changing, and the nanoparticle group absorbancy of parcel decline 22%.
Drug release in vitro test:
By 1 group of embodiment, sebacic acid-glycol copolymer directly the nanoparticle medicine group of the daptomycin of parcel and daptomycin ordinary preparation component have another name called get equivalent medicine (in daptomycin, every group containing 10mg daptomycin), then by each group of medicine as in test tube, after soaking with PBS damping fluid, 37 degrees Celsius of lower joltings in shaking table, after timing sampling, under ultraviolet spectrophotometer, measure the content of medicine, and the medicament contg per-cent that after record, calculating discharges, do releasing curve diagram, X-coordinate be the time (my god), ordinate zou is the per-cent discharging.See Fig. 2, the medicine that visible embodiment discharges is more permanent, makes drug half-life longer.
Solubility test in water:
By embodiment 1-2 group, sebacic acid-glycol copolymer directly the nanoparticle medicine group of the daptomycin of parcel and daptomycin ordinary preparation component have another name called get equivalent medicine (in daptomycin, every group containing 100mg daptomycin), put into respectively test tube, with the dissolving of 10mlPBS damping fluid jolting, situation is dissolved in static rear observation.The dissolved state that records 3 minutes and 20 minutes, result is as follows.
The comparison of table 1 solubleness
The therapeutic action of medicine to eye inflammation
1 laboratory animal
Healthy Wistar rat, male and female are not limit, and body weight is at 220g, observes intraocular in good condition and carry out this test without other eye illness person under slit lamp.
2 experimental techniques
2.1 modeling method
Carry out eyeground trauma infection contamination model, rat sucks etherization, on simple fixing and mouse plate, uses ophthalmology micro-surgical instrument on right eye temporo centered by 10 positions after elongation limbus of sclera 2 millimeters, does the arc incision parallel with corneoscleral junction, is about 3.0mm.Cut wall of eyeball holostrome, deeply reach vitreous space.Incision causes pigmented film incarceration, and pigmented film exposed parts is parallel with cutting edge, and otch will not be sewed up, and allows it produce and infects.
2.2 clustering method
Modeling success laboratory animal is divided into model group, embodiment 1-2 group, daptomycin ordinary preparation group at random, polymkeric substance directly wraps up nanoparticle subgroup prepared by daptomycin, the equal intravitreal 50 μ l medicines of each group, model group gives isopyknic PBS solution.
3 inspection items and method
Conventional fundoscopy grading marking
Every daily slit lamp, indirect ophthalmoscope inspection.After intervening, each treated animal was carried out to the scoring of endophthalmitis clinical scale in 1,4,7 day, primary part observation anterior chamber scintillation, aqueous cell and vitreous opacity degree, its grade scale is that (inflammatory exudate enters aqueous humor in anterior chamber's scintillation classification, under the narrow light belt of slit lamp casts oblique rays on, visible light flash and ooze out particle float, this phenomenon is called aqueous flare): 0 grade, without aqueous flare (light beam is transparent shinny); 1 grade, slight aqueous flare (the faint light beam that turns white); 2 grades, moderate aqueous flare (the milky white light beam of moderate can be distinguished iris and lens details); 3 grades, significantly aqueous flare (obvious milky white light beam, impalpable iris and lens details); 4 grades, serious anterior chamber's scintillation, aqueous humor becomes curdled appearance, with a large amount of fibrinous exudates.
4 statistical procedures
Data represent with x ± s, t inspection between relatively employing group between two groups.In the time of P < 0.05, for there being significant difference, there is statistical significance.
5 results
Clinical inflammation scoring
24h after sudden and violent leakage wound, there is palpebral edema in all rats, and corneal edema is obvious, and conjunctiva is congested, oedema obviously, anterior chamber's scintillation (+), exudation of anterior chamber (+).After intervening, within 4,7 days, carry out clinical inflammation scoring, model group inflammatory symptom increases the weight of day by day, and treatment group laboratory animal cornea is all transparent gradually, and anterior chamber's scintillation alleviates gradually, oozes out and is tending towards absorbing, and vitreous opacity alleviates in various degree.Each treatment group and model group more all have significant difference (table 1).
The clinical inflammation scoring of the each group of the postoperative different time points of table 1 situation (n > 10x ± s)
With relatively * p < 0.05 of model group, * * p < 0.01.
Claims (9)
1. in the structure being shown below, contain the segmented copolymer of daptomycin, its structure is as follows:
2. the multipolymer of claim 1, wherein PEG refers to polyoxyethylene glycol, and molecular weight is 100-100000, and wherein n does not represent stationary digital, is the integer of 1-200, preferably 1-100.
3. the preparation method of multipolymer as claimed in claim 1, is characterized in that:
1) obtain compd A with methoxy poly (ethylene glycol) amine and citric acid reactions;
2) reaction of the sebacic acid of compd A and ethanoyl obtains polymer B, and wherein n does not represent stationary digital, is the integer of 1-200, preferably 1-100;
3) polymer B is reacted and is obtained final product with daptomycin C;
compd A;
Daptomycin C
4. the method for claim 3, wherein said chemical step 1-3 selects solvent to be selected from: one or more in benzene, toluene, pyridine, tetrahydrofuran (THF), chloroform, tetracol phenixin, methylene dichloride, methyl alcohol, ethanol, methylene dichloride, dimethyl sulfoxide (DMSO), DMF.
5. the compound of claim 1 can be prepared into the nanometer formulation that is suitable for topical, microball preparation.
6. described in claim 5, part is intravitreal injection administration, dosing eyes.
7. the purposes of the compound of claim 1, purposes is the medicine of preparation treatment eye disease.
8. the purposes of the compound of claim 1, purposes is the medicine of preparation treatment ocular infection.
9. the purposes of claim 6, wherein eye disease refers to endophthalmitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210527557.1A CN103848894A (en) | 2012-11-30 | 2012-11-30 | Novel compound containing daptomycin structure as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210527557.1A CN103848894A (en) | 2012-11-30 | 2012-11-30 | Novel compound containing daptomycin structure as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103848894A true CN103848894A (en) | 2014-06-11 |
Family
ID=50857045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210527557.1A Pending CN103848894A (en) | 2012-11-30 | 2012-11-30 | Novel compound containing daptomycin structure as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103848894A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109476704A (en) * | 2016-04-08 | 2019-03-15 | 港大科桥有限公司 | Antibacterial cyclolipopeptide |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5578325A (en) * | 1993-07-23 | 1996-11-26 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| CN1404487A (en) * | 2000-01-20 | 2003-03-19 | 卡比斯特制药公司 | High-purity lipopeptide, lipopeptide micelles and preparation method thereof |
| WO2007016380A2 (en) * | 2005-07-28 | 2007-02-08 | (Osi) Eyetech, Inc. | Cyclitol linker polymer conjugate |
-
2012
- 2012-11-30 CN CN201210527557.1A patent/CN103848894A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5578325A (en) * | 1993-07-23 | 1996-11-26 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| CN1404487A (en) * | 2000-01-20 | 2003-03-19 | 卡比斯特制药公司 | High-purity lipopeptide, lipopeptide micelles and preparation method thereof |
| WO2007016380A2 (en) * | 2005-07-28 | 2007-02-08 | (Osi) Eyetech, Inc. | Cyclitol linker polymer conjugate |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109476704A (en) * | 2016-04-08 | 2019-03-15 | 港大科桥有限公司 | Antibacterial cyclolipopeptide |
| CN109476704B (en) * | 2016-04-08 | 2022-08-16 | 港大科桥有限公司 | Antibacterial cyclic lipopeptides |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Ocular biocompatibility and tolerance study of biodegradable polymeric micelles in the rabbit eye | |
| US20100222308A1 (en) | Ophthalmic, otic or nasal pharmaceutical composition and the use thereof | |
| CN103897174A (en) | Novel polymer containing ethacrynic acid structure, preparation method thereof and applications thereof | |
| CN101690809A (en) | Propolis-astragalus polysaccharides compound nanometer emulsion adjuvant and preparation method and application thereof | |
| CN103833998A (en) | Novel compound with ethacrynic acid structure as well as preparation method and application of novel compound | |
| Sheikh | Development and characterization of novel in situ gel of moxifloxacin hydrochloride | |
| Patil et al. | Design, optimization and pharmacodynamic comparison of dorzolamide hydrochloride soluble ocular drug insert prepared by using 32 factorial design | |
| Lam et al. | Randomized controlled trial on the safety of intracameral cephalosporins in cataract surgery | |
| CN103142468A (en) | Tacrolimus eye ointment for cornea transplantation and preparation method thereof | |
| CN105596336B (en) | Compound SR8278 is preparing the application in treating type-1 diabetes mellitus keratopathy drug | |
| Deshmukh et al. | In vitro and in vivo consideration of novel environmentally responsive ophthalmic drug delivery system | |
| CN103848852A (en) | New compound containing cephalosporin structure as well as preparation method and application thereof | |
| CN103848894A (en) | Novel compound containing daptomycin structure as well as preparation method and application thereof | |
| CN103848901A (en) | New compound containing vancomycin structure as well as preparation method and application thereof | |
| CN103897041A (en) | Novel compound containing vancomycin structure and preparation method and use thereof | |
| CN103910867A (en) | Nonlinear polymer having doxorubicin structure, and preparation method and application thereof | |
| CN103910868A (en) | Nonlinear polymer having doxorubicin structure, and preparation method and application thereof | |
| TW200918075A (en) | Compositions and methods for modulating endophthalmitis using fluoroquinolones | |
| Krenzer et al. | Safety of repeated topical ocular administration of a polycarbophil-based formulation in several models of ocular surgery in rabbits | |
| CN105566100A (en) | Styrene acid compound, composition containing same and application of styrene acid compound | |
| Fan et al. | Mefunidone Inhibits Inflammation, Oxidative Stress, and Epithelial-Mesenchymal Transition in Lens Epithelial Cells | |
| RU2730021C1 (en) | Topical agent for treating infectious vaginitis | |
| CN110279652B (en) | A kind of nanoemulsion gel eye drops for treating keratitis and preparation method | |
| Zheng et al. | Thermosensitive polyhedral oligomeric silsesquioxane hybrid hydrogel enhances the antibacterial efficiency of erythromycin in bacterial keratitis | |
| CN103865056A (en) | Nonlinear polymer containing doxorubicin structure, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140611 |
|
| WD01 | Invention patent application deemed withdrawn after publication |